137 related articles for article (PubMed ID: 29319843)
81. Modified vancomycin dosing protocol for treatment of diabetic foot infections.
Niu SC; Deng ST; Lee MH; Ho C; Chang HY; Liu FH
Am J Health Syst Pharm; 2008 Sep; 65(18):1740-3. PubMed ID: 18769001
[TBL] [Abstract][Full Text] [Related]
82. Staphylococcus aureus Central Nervous System Infections in Children.
Vallejo JG; Cain AN; Mason EO; Kaplan SL; Hultén KG
Pediatr Infect Dis J; 2017 Oct; 36(10):947-951. PubMed ID: 28399057
[TBL] [Abstract][Full Text] [Related]
83. Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.
Leroux S; Jacqz-Aigrain E; Biran V; Lopez E; Madeleneau D; Wallon C; Zana-Taïeb E; Virlouvet AL; Rioualen S; Zhao W
Antimicrob Agents Chemother; 2016 Apr; 60(4):2039-42. PubMed ID: 26787690
[TBL] [Abstract][Full Text] [Related]
84. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
[TBL] [Abstract][Full Text] [Related]
85. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.
Hong J; Krop LC; Johns T; Pai MP
Pharmacotherapy; 2015 May; 35(5):455-63. PubMed ID: 26011138
[TBL] [Abstract][Full Text] [Related]
86. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.
Wong-Beringer A; Joo J; Tse E; Beringer P
Int J Antimicrob Agents; 2011 Feb; 37(2):95-101. PubMed ID: 21130609
[TBL] [Abstract][Full Text] [Related]
87. Aerosolized vancomycin for the treatment of MRSA after lung transplantation.
Hayes D; Murphy BS; Mullett TW; Feola DJ
Respirology; 2010 Jan; 15(1):184-6. PubMed ID: 19895389
[TBL] [Abstract][Full Text] [Related]
88. Vancomycin prophylaxis in paediatric patients following cardiac surgery: a retrospective evaluation of trough levels and associated variables.
Vallesi L; Fragasso T; Benegni S; Insom G; Di Chiara L; Corsetti T; Ricci Z
Interact Cardiovasc Thorac Surg; 2020 Nov; 31(5):667-673. PubMed ID: 32984899
[TBL] [Abstract][Full Text] [Related]
89. Evaluation for optimal dosing of vancomycin in patients with different physical types.
Hashimoto M; Iketani O; Ichinose N; Enoki Y; Taguchi K; Uno S; Uwamino Y; Hasegawa N; Matsumoto K
J Infect Chemother; 2019 Sep; 25(9):735-737. PubMed ID: 31126752
[TBL] [Abstract][Full Text] [Related]
90. Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults.
Maki N; Ohkuchi A; Tashiro Y; Kim MR; Le M; Sakamoto T; Matsubara S; Hakamata Y
Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2537-43. PubMed ID: 22391760
[TBL] [Abstract][Full Text] [Related]
91. Does vancomycin administered at an empirical dose ensure coverage of pediatric patients against gram-positive pathogens?
Pires FR; Paula SI; Delgado AF; Carvalho WB; Duarte NJC; Morales Júnior R; Santos SRCJ
Rev Bras Ter Intensiva; 2020; 32(3):391-397. PubMed ID: 33053028
[TBL] [Abstract][Full Text] [Related]
92. Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis.
Lindley B; Bhakta Z; Gray K; Watanabe A; Leclair L; Young DC
Pediatr Pulmonol; 2022 Nov; 57(11):2646-2651. PubMed ID: 35836330
[TBL] [Abstract][Full Text] [Related]
93. Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients.
Bauernfeind A; Przyklenk B; Matthias C; Jungwirth R; Bertele RM; Harms K
Infection; 1990; 18(2):126-30. PubMed ID: 2332248
[TBL] [Abstract][Full Text] [Related]
94. The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis.
Lindley B; Bhakta Z; Leclair L; Young DC
Pediatr Pulmonol; 2024 Jan; 59(1):89-94. PubMed ID: 37792309
[TBL] [Abstract][Full Text] [Related]
95. Factors influencing the vancomycin trough level in patients admitted at King Fahad Specialist Hospital, Qassim, KSA.
Altowayan WM; Mobark MA; Alharbi AS; Alduhami AA; Rabbani SI
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4840-4845. PubMed ID: 35856376
[TBL] [Abstract][Full Text] [Related]
96. Low vancomycin trough concentration in neonates and young infants.
Maruyama H; Tanzawa A; Funaki T; Ito Y; Isayama T
Pediatr Int; 2021 May; 63(5):556-560. PubMed ID: 32894884
[TBL] [Abstract][Full Text] [Related]
97. Dose Optimization of Vancomycin Using a Mechanism-based Exposure-Response Model in Pediatric Infectious Disease Patients.
Jung WJ; Park JH; Goo S; Chae JW; Kim J; Shin S; Yun HY
Clin Ther; 2021 Jan; 43(1):185-194.e16. PubMed ID: 33358258
[TBL] [Abstract][Full Text] [Related]
98. Special considerations for monitoring vancomycin concentrations in pediatric patients.
Miles MV; Li L; Lakkis H; Youngblood J; McGinnis P
Ther Drug Monit; 1997 Jun; 19(3):265-70. PubMed ID: 9200765
[TBL] [Abstract][Full Text] [Related]
99. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants.
Lisby-Sutch SM; Nahata MC
Eur J Clin Pharmacol; 1988; 35(6):637-42. PubMed ID: 3234472
[TBL] [Abstract][Full Text] [Related]
100. Pharmacokinetics of vancomycin in adult cystic fibrosis patients.
Pleasants RA; Michalets EL; Williams DM; Samuelson WM; Rehm JR; Knowles MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):186-90. PubMed ID: 8787903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
